Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (331-340 of 377) with videos related to

Pageof 38
Sort By:
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Breast Cancer Research and Treatment|October 17, 2018
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysisPeter A Fasching, Andreas D Hartkopf, Paul Gass, et al.
NPJ Breast Cancer|July 13, 2024
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancerPeter A Fasching, Chunling Hu, Steven N Hart, et al.
The New England Journal of Medicine|January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast CancerCharles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization TrialMartine Piccart-Gebhart, Eileen Holmes, José Baselga, et al.
Journal of the National Cancer Institute. Monographs|November 2, 2011
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)Alfredo Berruti, Daniele Generali, Manfred Kaufmann, et al.
JCO Precision Oncology|September 2, 2025
Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment StrategiesEric Hahnen, Jan Hauke, Karen Gelmon, et al.
Cell Reports. Medicine|November 20, 2024
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancerCarsten Denkert, Andreas Schneeweiss, Julia Rey, et al.
JCO Precision Oncology|April 10, 2025
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study AnalysisEric Hahnen, Jan Hauke, Karen Gelmon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 23, 2026
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial CohortCarsten Denkert, Sivaramakrishna Rachakonda, Anika Pehl, et al.
Pageof 38

Showing results (331-340 of 377) with videos related to

Sort By:
Pageof 38
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Breast Cancer Research and Treatment|October 17, 2018
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysisPeter A Fasching, Andreas D Hartkopf, Paul Gass, et al.
NPJ Breast Cancer|July 13, 2024
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancerPeter A Fasching, Chunling Hu, Steven N Hart, et al.
The New England Journal of Medicine|January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast CancerCharles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization TrialMartine Piccart-Gebhart, Eileen Holmes, José Baselga, et al.
Journal of the National Cancer Institute. Monographs|November 2, 2011
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)Alfredo Berruti, Daniele Generali, Manfred Kaufmann, et al.
JCO Precision Oncology|September 2, 2025
Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment StrategiesEric Hahnen, Jan Hauke, Karen Gelmon, et al.
Cell Reports. Medicine|November 20, 2024
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancerCarsten Denkert, Andreas Schneeweiss, Julia Rey, et al.
JCO Precision Oncology|April 10, 2025
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study AnalysisEric Hahnen, Jan Hauke, Karen Gelmon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 23, 2026
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial CohortCarsten Denkert, Sivaramakrishna Rachakonda, Anika Pehl, et al.
Pageof 38